This database contains 202 studies, archived under the term: "drug effects"
Click here to filter this large number of results.
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia
Sommer, Oskar H.,
Aga, Olav,
Cvancarova, Milada,
Olsen, Inge C.,
Selbaek, Geir,
Engedal, Knut
Background/aims: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with Alzheimer’s disease, vascular dementia or both.; Methods: This is an 8-week, multicenter, randomized, double-blind, placebo-controlled trial carried out independently of the pharmaceutical industry. Changes in the agitation and aggression subscore of the Neuropsychiatric Inventory (NPI) were the […]
Ginkgo biloba for preventing cognitive decline in older adults: a randomized trial
Snitz, Beth E.,
O'Meara, Ellen S.,
Carlson, Michelle C.,
Arnold, Alice M.,
Ives, Diane G.,
Rapp, Stephen R.,
Saxton, Judith,
Lopez, Oscar L.,
Dunn, Leslie O.,
Sink, Kaycee M.,
DeKosky, Steven T.
Context: The herbal product Ginkgo biloba is taken frequently with the intention of improving cognitive health in aging. However, evidence from adequately powered clinical trials is lacking regarding its effect on long-term cognitive functioning.; Objective: To determine whether G. biloba slows the rates of global or domain-specific cognitive decline in older adults.; Design, Setting, and […]
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S.,
Sperling, R.,
Gilman, S.,
Fox, N. C.,
Blennow, K.,
Raskind, M.,
Sabbagh, M.,
Honig, L. S.,
Doody, R.,
van Dyck, C. H.,
Mulnard, R.,
Barakos, J.,
Gregg, K. M.,
Liu, E.,
Lieberburg, I.,
Schenk, D.,
Black, R.,
Grundman, M.
Background: Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.; Methods: The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). […]
The effects of glucose ingestion and glucose regulation on memory performance in older adults with mild cognitive impairment
Riby, L. M.,
Marriott, A.,
Bullock, R.,
Hancock, J.,
Smallwood, J.,
McLaughlin, J.
Background/objectives: Previous research investigating the impact of glucose ingestion and/or improvements in glucose regulation has found selective cognitive facilitation on episodic memory tasks in successful ageing and dementia. The present study aimed to extend this research to mild cognitive impairment (MCI).; Subjects/methods: In a repeated-measures design, 24 older adults with and 24 older adults without […]
Effects of donepezil on cortical activation in mild cognitive impairment: a pilot double-blind placebo-controlled trial using functional MR imaging
Petrella, J. R.,
Prince, S. E.,
Krishnan, S.,
Husn, H.,
Kelley, L.,
Doraiswamy, P. M.
Background and Purpose: Cholinesterase-inhibitor therapy is approved for treatment of Alzheimer disease; however, application in patients with mild cognitive impairment (MCI) is still under active investigation. The purpose of this study was to determine the effect of such therapy on the neural substrates underlying memory processing in subjects with MCI by using functional MR imaging […]
Clinical effects of high oral dose of donepezil for patients with Alzheimer’s disease in Japan
Nozawa, Motohiro,
Ichimiya, Yosuke,
Nozawa, Eiko,
Utumi, Yushi,
Sugiyama, Hideki,
Murayama, Norio,
Iseki, Eizo,
Arai, Heii
Background: Donepezil 10 mg/day gained approval in Japan in August 2007 for the treatment of cognitive dysfunction in advanced Alzheimer’s disease.; Methods: We evaluated the efficacy and adverse effects of donepezil when the dose was increased to 10 mg/day in 61 Japanese patients with Alzheimer’s disease. Cognitive function was evaluated using the Revised Hasegawa Dementia […]
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients
Nordberg, Agneta,
Darreh-Shori, Taher,
Peskind, Elaine,
Soininen, Hilkka,
Mousavi, Malahat,
Eagle, Gina,
Lane, Roger
Background: The current study aimed to compare the effects of different cholinesterase inhibitors on acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) activities and protein levels, in the cerebrospinal fluid (CSF) of Alzheimer disease (AD) patients.; Methods and Findings: AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. […]